QuidMora LLC

*QuidMora is a next generation portfolio management business. Our focus is pipeline analysis, and o

06/07/2016

How to be smarter than your brain

https://www.choprafoundation.org/articles/how-to-be-smarter-than-your-brain/

Among all the sciences, neuroscience is a special case. Because it studies the brain, which is our interface with the mind, neuroscience covers the widest

06/06/2016

Antibody Drug Conjugates (ADCs) are paving the way for next generation targeted cancer therapies

http://adcreview.com/news/linkers-for-antibody-drug-conjugates-current-role-and-advancements/

Advancements in research have shifted the way we think of combating cancer, and traditional treatment options are on the path to being replaced by safer and more effective methods. Antibody-drug conjugates, or ADCs, are at the forefront of this change. They and are being developed to meet the challe...

06/05/2016

Interesting research on how to activate/deactivate our own immune cycle to effectively fight cancer

http://www.gene.com/stories/tipping-the-scales

With OX40, we may have found a way to activate the body’s immune system to fight cancer.

06/04/2016

First blood test aiding in early detection of non-small cell lung carcinoma.

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm504488.htm

The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved, blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-sma...

06/03/2016

Leading CRO in Asia-Pacific region

http://www.novotech-cro.com/locations

We have the broadest midsize CRO footprint in Asia-Pac, with offices in 18 locations, across 12 countries.

06/03/2016

How startup entrepreneurs can find a product market fit

http://rein.pk/finding-product-market-fit?utm_content=buffer62ad4&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer

Co-founder and CEO at Segment, ex-MIT. Lots to learn.

06/03/2016

The process of patient enrollment in oncology studies varies greatly. Still, this article offers simple answers to why some of those studies finish late and why over budget.

http://www.medelis.com/why-oncology-studies-finish-late-and-over-budget/?platform=hootsuite

The number one reason why oncology studies fail to meet their enrollment targets boils down to site selection. Learn how to not fall into the common traps.

05/26/2016

Interesting attempt for a company to predict a successful launch of 20 new drugs in the near future.
http://www.biopharmadive.com/news/despite-recent-rd-setbacks-lilly-aims-to-launch-20-new-drugs-by-2023/419760/

Although Lilly has struggled to replace aging drugs, CEO John Lechleiter sees the decade from 2014 to 2013 as "he most prolific period of new launches" in the company's history.

12/09/2015

Another potential blockbuster (Osimerinib) is now approved:
http://www.biopharmadive.com/news/in-major-victory-astrazeneca-wins-fda-approval-for-potential-3b-lung-canc/409207/

Tagrisso (osimerinib) is now approved for second-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).

12/09/2015

http://www.pharmamicroresources.com/2015/11/pharmaceutical-microbiology-essentials.html

Microbiology, pharmaceuticals, healthcare and contamination control news and discussion site. Edited by Dr. Tim Sandle (established 2010)

Address

Sammamish, WA
98074

Website

http://www.QuidMora.com/

Alerts

Be the first to know and let us send you an email when QuidMora LLC posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your business to be the top-listed Business in Sammamish?

QuidMora LLC

06/07/2016

06/06/2016

06/05/2016

06/04/2016

06/03/2016

06/03/2016

06/03/2016

05/26/2016

12/09/2015

12/09/2015

Address

Website

Alerts

Shortcuts

Share

Category